NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
Clinical Trials
15 trialsNCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT04639180 2025-12-30
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04581473 2025-06-05
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT04073615 2024-05-02
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
Elevar Therapeutics
Phase 1 Terminated
NCT02329860 2024-01-22
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT02711969 2022-07-22
A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
Bukwang Pharmaceutical
Phase 1 Completed
NCT03707028 2022-04-11
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Elevar Therapeutics
Phase 1/2 Terminated
NCT02764268 2022-03-11
Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase NA Completed
NCT03026881 2017-03-07
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT01512745 2016-10-17
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01531777 2015-04-03
Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed